About 260 Mg Paclitaxel Injection IP
Elevate oncology care with the elite 260 Mg Paclitaxel Injection IP, a marvelously formulated, preservative-free antineoplastic agent crafted under strict USP standards. Each wondrous glass vial contains a clear to pale yellow solution (43.4 mg/ml, 5 ml pack), ready for instant checkout by distributors, suppliers, and traders across India. Specifically manufactured for intravenous use, this unbeatable, single-dose medicine supports the treatment of ovarian, breast, and non-small cell lung cancers. Prescribed by professionals only, it ensures no visible particles and offers compatibility with both saline and dextrose infusions. Cytotoxic warning applies; careful handling is essential.
Dedicated Intravenous Application & Oncologic Uses
260 Mg Paclitaxel Injection IP is marvelously designed for intravenous infusion, ensuring rapid, direct delivery to the bloodstream. It is principally used as an antineoplastic agent in ovarian, breast, and non-small cell lung cancers. This preservative-free formulation is suitable for hospital and clinic settings, benefiting patients needing elite chemotherapy regimens. The clear-to-pale yellow solution is compatible with both saline and dextrose, supporting versatile clinical applications in oncology.
Sample Availability, Delivery Logistics & Supply Management
Sample vials of 260 Mg Paclitaxel Injection IP are readily available for healthcare institutions seeking quality verification. Goods transport is organized efficiently, ensuring timely order completion even for bulk purchases. Our robust supply ability supports continuous demand in both local and exporting markets. Freight arrangements are handled with utmost care so products reach safely and securely, making the entire procurement process seamless for authorized buyers.
FAQ's of 260 Mg Paclitaxel Injection IP:
Q: How should 260 Mg Paclitaxel Injection IP be administered?
A: This injection is intended exclusively for intravenous infusion, administered by a healthcare professional in a clinical or hospital setting. Dosage timing and volume are determined by the patient's specific condition and physician's instructions.
Q: What are the primary indications for using Paclitaxel 260 mg Injection?
A: It is primarily indicated for the treatment of various cancers, including ovarian cancer, breast cancer, and non-small cell lung cancer. Your oncologist will evaluate its suitability based on your diagnosis.
Q: When can I expect delivery after placing an order for this injection?
A: We ensure that freight and goods transport are coordinated promptly following order completion, with delivery timelines dependent on your location and order size. Most shipments are dispatched within standard pharmaceutical delivery timeframes.
Q: Where is the 260 Mg Paclitaxel Injection IP manufactured and supplied from?
A: This product is distributed, exported, and supplied from licensed pharmaceutical distributors and traders based in India, who ensure compliance with all USP quality standards.
Q: What process should be followed to handle this medication safely?
A: As a cytotoxic agent, it must be handled by trained professionals wearing appropriate protective equipment. Follow hospital protocol for preparation, administration, and disposal to safeguard both patients and staff.
Q: How can healthcare centers request samples of this injection?
A: Healthcare institutions can contact authorized distributors or suppliers to request sample vials for evaluation purposes before finalizing procurement contracts.